Keywords
How to Cite
Abstract
Introduction. The article discusses modern methods of combined treatment of patients with cerebral and visceral metastases of melanoma, including drug therapy and radiation therapy, the place of neurosurgery, and also discusses a clinical case of long-term relapse-free survival after effective treatment of multiple intracerebral and extracranial metastases of non-pigmented melanoma without a driver mutations.
Purpose. Analysis of the results of the application of modern methods of antitumor treatment of melanoma with metastases to the brain and their effect on survival on the example of a clinical case of a patient with metastatic non-pigmented melanoma without an identified primary focus without driver mutations with multiple metastases to the brain, single metastases to the cervical lymph node and left adrenal gland.
Materials and methods. Using a clinical example, a possible sequence of an individual approach to the treatment of a patient with multiple intracerebral metastases of non-pigmented melanoma without a primary identified focus without driver mutations and metastasis to the left adrenal gland is considered, the place of modern methods of treatment and examination.
Results. The use of a combination of modern methods of anticancer therapy, including immunotherapy, stereotactic radiosurgery and radiation therapy, has increased the overall and relapse-free survival of patients with metastases of melanoma to the brain and visceral organs, and, moreover, reduces the need in neurosurgical interventions. As confirmation of this, the patient is alive for more than 25 months from the moment of progression with a life expectancy of 3-6 months.
Conclusions. Modern methods of anticancer therapy can significantly increase the survival rate of patients with metastases of melanoma to the brain and visceral organs, and the accumulation of clinical experience will contribute to the optimization of approaches in the combined and sequential treatment of metastatic melanoma.
References
Меланома кожи и слизистых оболочек. Клинические рекомендации. 2020. doi:oncology-association.ru/wp-content/uploads/2020/09/melanoma_kozhi.pdf [Melanoma of the skin and mucous membranes. Clinical guidelines. 2020 (In Russ.)]. doi:oncology-association.ru/wp-content/uploads/2020/09/melanoma_kozhi.pdf
Каприн А.Д., Старинский В.В., Петрова В.В. Злокачественные новообразования в России в 2018 году. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2019 [Kaprin AD, Starinskiy VV, Petrova VV. Malignant neoplasms in Russia in 2018. M.: MNIOI them. P.A. Herzen — branch of the Federal State Budgetary Institution «NMIRC» of the Ministry of Health of Russia, 2019 (In Russ.)].
Куржупов М.И. Возможности лечения диссеминированной меланомы с множественным метастатическим поражением головного мозга // Исследования и практика в медицине 2018;5(4):98−105. doi:10.17709/2409-2231-2018-5-4-10 [Kurzhupov MI. Treatment options for disseminated melanoma with multiple metastatic brain lesions // Research and Practice in Medicine. 2018;5(4):98−105 (In Russ.)]. doi:10.17709 / 2409-2231-2018-5-4-10
Long GV, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies // Am Soc Clin Oncol Educ Book 2013;393–8. doi:10.14694/EdBook_AM.2013.33.393
Kircher DA et al. Melanoma Brain Metastasis: Mechanisms, Models, and Medicine // Int J Mol Sci. 2016;17:1468. doi:10.3390/ijms17091468
Cohen JV et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities // Pigment Cell Melanoma Res. 2016;29:627–642. doi:10.1111/pcmr.12538
Staudt M et al. Determinants of survival in patients with brain metastases from cutaneous melanoma // Br J Canc. 2010;102:1213–1218. doi:10.1038/sj.bjc.6605622
Hong AM et al. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial // J Clin Oncol. 2019;37(33):3132–3141. doi:10.1200/JCO.19.01414
Linda Chen et al. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma // Int J Radiat Oncol Biol Phys. 2018;100(4):916–925. doi:10.1016/j.ijrobp.2017.11.041
Richard J White et al. Melanoma brain metastases: is it time to eliminate radiotherapy? // J Neurooncol. 2020;149(1):27–33. doi:10.1007/s11060-020-03485-w
Насхлеташвили Д.Р., Банов С.М., Бекяшев А.Х. и др. Практические рекомендации по лекарственному лечению метастатических опухолей головного мозга // Злокачественные опухоли. 2016;4(2):85–96 [Naskhletashvili DR, Banov SM, Bekyashev AKh et al. Practical recommendations for drug treatment of metastatic brain tumors // Malignant tumors. 2016;4(2):85–96 (In Russ.)].
Davies MA et al. Prognostic factors for survival in melanoma patients with brain metastases // Cancer. 2011;117(8):1687–96. doi:10.1002/cncr.25634. Epub 2010 Oct 19
Насхлеташвили Д. Р., Банов С. М., Бекяшев А. Х. и др. Практические рекомендации по лекарственному лечению метастатических опухолей головного мозга // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018;8:100–112 [Naskhletashvili DR, Banov SM, Bekyashev AKh et al. Practical recommendations for drug treatment of metastatic brain tumors // Malignant tumors: Practical recommendations of RUSSCO # 3s2. 2018;8:100–112 (In Russ.)].
Long GV, Atkinson V, Lo S. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study // Lancet Oncol. 2018;19(5):672−81. doi:10.1016/S1470-2045(18)30139-6
Long GV, Atkinson VG, Lo S. et al. Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo1ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) // Annals of Oncology. 2019;30(5):534.
Larkin J et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma // N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021